ICU Medical (ICUI) Earnings Date & Reports

Key Takeaways

• ICU Medical reported fourth-quarter 2025 revenue of $540.7 million, down roughly 14% year over year, reflecting the May 2025 divestiture of its IV Solutions business into a joint venture.
• Adjusted diluted earnings per share (EPS) came in at $1.91, above the consensus estimate of about $1.71, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was $98.2 million.
• Organic revenue grew 2% in the quarter and 5% for the full year, led by record results in the Consumables and Infusion Systems segments.
• For fiscal 2026, management guided to adjusted EPS of $7.75 to $8.45 and adjusted EBITDA of $400 million to $430 million.
• Tariffs remained a headwind, reducing adjusted EBITDA by roughly $25 million for the year, with a similar drag expected to persist into 2026.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore our dedicated pages for a deeper look at how the market is positioning around ICUI.
• You can also discover new opportunities by exploring Trending AI Robots, which surface AI-driven trading ideas across a broad universe of stocks and ETFs.

Earnings Context and Why It Matters

ICU Medical's fourth-quarter results close out a pivotal year for the infusion-therapy and critical-care device maker. The company spent 2025 integrating the Smiths Medical acquisition while completing the disposition of its IV Solutions business into the Otsuka-ICU Medical joint venture, a move that reshaped its reported revenue profile. Those structural changes make year-over-year comparisons less meaningful on a headline basis, pushing investors to focus on organic growth and margin progress instead. With adjusted gross margin holding above 40% and adjusted EBITDA recovering from integration-related pressure, the report offers a key checkpoint on whether management's multi-year turnaround is translating into durable, higher-quality earnings as the company pivots toward growth in its core consumables and infusion systems franchises.

Reported Results

For the quarter ended December 31, 2025, ICU Medical posted total revenue of $540.7 million, compared with $629.8 million a year earlier. The decline primarily reflects the deconsolidation of the IV Solutions business, which was contributed to the Otsuka-ICU Medical joint venture effective May 1, 2025. On an organic basis, revenue rose 2%, and full-year organic growth reached 5%.

GAAP (Generally Accepted Accounting Principles) net loss narrowed to $15.7 million, or $0.64 per diluted share, from a loss of $23.8 million, or $0.97 per share, in the prior-year quarter. Adjusted diluted EPS was $1.91, down from $2.11 a year ago but above the roughly $1.71 consensus estimate. Adjusted EBITDA declined to $98.2 million from $105.5 million, pressured by the IV Solutions deconsolidation and about $11 million of tariff expense in the quarter.

By product line, Consumables revenue rose to $284.7 million and Infusion Systems grew to $176.3 million, while Vital Care declined to $79.7 million, reflecting the IV Solutions divestiture. For fiscal 2026, the company guided to GAAP EPS of $1.03 to $1.74, adjusted EPS of $7.75 to $8.45, and adjusted EBITDA of $400 million to $430 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. By automating the screening process, the tool helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual research. Explore the AI Screener to uncover ideas aligned with your own strategy.

Market Reaction and Investor Sentiment

ICU Medical's results were broadly in line with its own expectations, and the adjusted EPS beat relative to consensus provided a modest positive signal. However, sentiment heading into the print was already tempered by the structural revenue decline from the IV Solutions divestiture and the ongoing tariff burden. The company's closing of the U.S. Food and Drug Administration (FDA) warning letter tied to its legacy Smiths Medical operations was a notable operational milestone, easing a regulatory overhang. At the same time, the 2026 adjusted EBITDA guidance of $400 million to $430 million remains below the company's earlier longer-term targets, which has kept investors focused on execution rather than rewarding the quarter outright.

Forward Outlook and Key Factors to Monitor

Looking ahead, management's 2026 guidance implies low- to mid-single-digit organic revenue growth, adjusted gross margin of roughly 41%, and a continued emphasis on free cash flow generation and debt reduction. Tariffs are expected to pressure gross margin by approximately 2% of revenue during the year, an issue management is addressing through supply-chain and manufacturing changes that may take time to fully materialize.

Investors should watch whether the Consumables and Infusion Systems segments sustain their momentum, given management's confidence in mid-single-digit growth. The Smiths Medical integration remains a central theme, with completed site consolidations expected to unlock further synergies. Capital-market activity around the company's pump portfolio, including the Duo and Solo platforms in the U.S. and the international product lineup, will also be an important demand signal.

Finally, balance-sheet progress matters. With net debt just below $1 billion and a target of roughly 2x net leverage by early 2027, disciplined cash deployment and any commentary on returning capital to shareholders could shape sentiment in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations